RT Journal Article
SR Electronic
T1 SARS-CoV-2 viral load monitoring by extraction-free testing of saliva
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.08.02.21261502
DO 10.1101/2021.08.02.21261502
A1 Qiu, Yue
A1 Lu, Ling
A1 Gao, Dexiang
A1 McGrath, Patrick
A1 Han, Chann
A1 Kogut, Igor
A1 Blomquist, Bob
A1 Yao, Xin
A1 Zevallos, Jose P.
A1 Harry, Brian L.
A1 Lu, Shi-Long
YR 2021
UL http://medrxiv.org/content/early/2021/08/04/2021.08.02.21261502.abstract
AB Real-time quantitative reverse transcriptase polymerase chain reaction (RT-qPCR) remains the foundation of SARS-CoV-2 testing due to its accessibility, scalability, and superior assay performance. Variability in specimens and methods prevent standardization of RT-qPCR assays and reliable quantitative reporting to assess viral load. We developed an extraction-free RT-qPCR assay for detection of SARS-CoV-2 in saliva and monitored viral load until convalescence in COVID-19 patients. Comparison of 231 matched anterior nares swab and saliva specimens demonstrated that extraction-free testing of saliva has equivalent analytical and clinical assay performance compared to testing of RNA extracts from either anterior nares or saliva specimens. Analysis of specimen pairs revealed higher viral loads in the nasal cavity compared to the oral cavity, although this difference did not impact clinical sensitivity for COVID-19. Extraction-free testing of a combination specimen consisting of both nasal swab and saliva is also demonstrated. Assessment of viral load by RT-qPCR and parallel digital droplet PCR (ddPCR) revealed that cycle threshold (Ct) values less than approximately 30 correlated well with viral load, whereas Ct values greater than 30 correspond to low viral loads <10 copies/µL. Therefore, extraction-free saliva testing maximizes testing efficiency without compromising assay performance and approximates viral loads >10 copies/µL. This technology can facilitate high-throughput laboratory testing for SARS-CoV-2, monitor viral load in individual patients, and assess efficacy of therapies for COVID-19.Competing Interest StatementDG, BB, XY, JZ, BH, and SL own equity in Summit Biolabs, Inc.Funding StatementFunding of the study is provided by University of Colorado Anschutz Medical Campus SPARK program, University of Colorado Anschutz Medical Campus Chancellor Discovery Innovation Fund (CDI Fund), AIA, and Summit Biolabs, Inc.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Salus IRB Summit Biolabs, Inc./ Summit-COVID-SLV-1/ Brian Harry, MD PhDAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is presented in the manuscript